Literature DB >> 2613484

Assessment of liver ability to biotransformation of antipyrine in uraemic patients on regular peritoneal dialysis treatment.

A Grzegorzewska1, Z Lowicki, E Chmara, A Mrozikiewicz, K Baczyk.   

Abstract

It was the aim of this work to establish whether biotransformation of drugs by the liver expressed by antipyrine kinetics is disturbed in peritoneally dialysed patients with end-stage renal failure. The investigations were carried out in 10 uraemic patients using the antipyrine test and comparing the parameters of antipyrine kinetics with those obtained in 13 healthy persons. Our results indicate that in uraemic patients on regular peritoneal dialysis treatment antipyrine kinetics are generally in the normal range, suggesting the microsomal content of cytochrome P-450 being not evidently reduced.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2613484     DOI: 10.1007/bf02549593

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  20 in total

1.  Elimination and serum protein binding of phenylbutazone in patients with renal insufficiency.

Authors:  H Held; C Enderle
Journal:  Clin Nephrol       Date:  1976-09       Impact factor: 0.975

2.  The use of antipyrine in the measurement of total body water in man.

Authors:  R SOBERMAN; B B BRODIE
Journal:  J Biol Chem       Date:  1949-05       Impact factor: 5.157

3.  The estimation of antipyrine in biological materials.

Authors:  B B BRODIE; J AXELROD
Journal:  J Biol Chem       Date:  1949-05       Impact factor: 5.157

4.  Enzyme induction in the uremic liver.

Authors:  H W Leber; L Gleumes; G Schütterle
Journal:  Kidney Int Suppl       Date:  1978-06       Impact factor: 10.545

5.  Environmental effects on antipyrine half-life in man.

Authors:  H S Fraser; J C Mucklow; C J Bulpitt; C Khan; G Mould; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

6.  The metabolism of antipyrine in patients with chronic renal failure.

Authors:  M Lichter; M Black; I M Arias
Journal:  J Pharmacol Exp Ther       Date:  1973-12       Impact factor: 4.030

7.  [Studies on the effect of uremia on phenylbutazone and aminophenazone metabolism in man].

Authors:  H W Leber; A Harders; G Schütterle
Journal:  Klin Wochenschr       Date:  1972-12-01

8.  Mechanism of hepatic drug oxidation and its relationship to individual differences in rates of oxidation in man.

Authors:  D S Davies; S S Thorgeirsson
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

9.  [Effect of labetalol on antipyrine metabolism in the liver].

Authors:  H Adamska-Dyniewska; S Dziekański
Journal:  Pol Arch Med Wewn       Date:  1984-03

10.  [Liver capacity in the biotransformation of drugs in patients with chronic circulatory failure (kinetics of antipyrine and indocyanine green)].

Authors:  H Adamska-Dyniewska
Journal:  Pol Arch Med Wewn       Date:  1978-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.